Advancements in High-Speed DNA Synthesis to Drive Growth in the Global Synthetic Biology Market
Advancements in High-Speed DNA Synthesis to Drive Growth in the Global Synthetic Biology Market, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Synthetic Biology markets. Global market for Synthetic Biology is projected to reach US$12.9 billion by 2018, driven by advances in high-speed DNA synthesis and DNA sequencing.
[caption id="attachment_144" align="aligncenter" width="500"] High-Speed DNA Synthesis to Drive Growth in Synthetic Biology Market[/caption]
San Jose, California (PRWEB) November 26, 2013
Follow us on LinkedIn - Synthetic biology as an extension of biotechnology and genetic engineering, is expected to present a new world of opportunities right from designing new biological systems to entirely transforming the way food crops or medicines are developed. Unlike genetic engineering, in synthetic biology, scientists entirely reengineer biological systems by writing a new genetic code on a computer, which is later impregnated into organisms for creating an artificial life form. Though synthetic biology is still in its infancy, the potential for future impact remains significant. The revolutionary idea brings together multiple disciplines such as computer modeling, engineering and biological sciences for creating next-generation biological systems, parts and devices as well as for redesigning existingbiological systems for useful applications. Molecular biologists, computer scientists, engineers and chemists are working in collaboration to develop building blocks for creating a new synthetic world, while researchers are exploring the process of gene manipulation as well as reconfiguration of metabolic pathways of cells to perform new functions. Ever since its inception, synthetic biology has played a pioneering role in transforming applications across diverse end-use segments including agriculture, pharmaceuticals, energy and healthcare. Several of the leading chemical, energy, pharmaceutical, food, forestry and agribusiness companies are investing in synthetic biology research and are increasingly relying on artificial DNA fragments to invent new products.
As stated by the new market research report on, Synthetic Biology, Europe represents the largest market worldwide, supported by high R&D interest in developing synthetic biology based products. Within Europe, Germany, the UK and Scotland remain prominent markets. Japan, India and China are expected to drive future growth in the market.
Synthetic biology has potential applications in a number of areas, including health, environment, energy, food and agriculture and new materials development. Energy & Chemicals represent the largest as well as the fastest growing end-use sector. Within the pharmaceuticals sector, the technology has pioneered the development of an affordable and highly-effective malaria drug, which offers therapeutic benefits similar to Artemisia, a Chinese herb. The new drug is produced inside the cellular membranes of a synthetic yeast strain. In the agriculture sector, the technology finds utility in the production of genetically-engineered crops. Currently, genetically-engineered crops contribute about 94% of cotton, 93% of soy, and 88% of corn of the overall acreage in the United States. The technology is being used to develop high-performance biofuels. Other areas with commercial potential include the use of synthetic biology for creating crop-enhancing fertilizers and new food additives, such as artificial sweeteners. The technology can also be used to modify the genetic code of naturally-found bacteria in the soil so that it releases growth hormones in soil for the plant to absorb the hormone and develop stronger roots. Synthetic biology can also be used to create gene network for endangered species, facilitate artificial photosynthesis, and perform biological computing.
Major players covered in the report include Agilent Technologies Inc., Amyris Biotechnologies Inc., BP PLC, Chromatin Inc., DuPont, Gevo Inc., 454 Life Sciences, Epoch Life Science Inc., Evolva SA, Solazyme Inc., Synthetic Genomics Inc., Synthetic Biologics Inc., DNA2.0, Intrexon Corp, and Life Technologies, among others.
The research report titled "Synthetic Biology: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, drivers, issues, and strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific and Rest of World. The report analyzes the global market for synthetic biology by end-use sector - Energy & Chemicals, Biotechnology & Pharmaceuticals and Research & Development.
For more details about this comprehensive market research report, please visit -http://www.strategyr.com/Synthetic_Biology_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Follow us on LinkedIn
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
News Release Source : http://www.prweb.com/releases/synthetic_biology_market/bioengineering_industry/prweb11371207.htm